Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection.
Nat Commun
; 13(1): 6439, 2022 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: covidwho-2096707
ABSTRACT
Measles is the most contagious airborne viral infection and the leading cause of child death among vaccine-preventable diseases. We show here that aerosolized lipopeptide fusion inhibitor, derived from heptad-repeat regions of the measles virus (MeV) fusion protein, blocks respiratory MeV infection in a non-human primate model, the cynomolgus macaque. We use a custom-designed mesh nebulizer to ensure efficient aerosol delivery of peptide to the respiratory tract and demonstrate the absence of adverse effects and lung pathology in macaques. The nebulized peptide efficiently prevents MeV infection, resulting in the complete absence of MeV RNA, MeV-infected cells, and MeV-specific humoral responses in treated animals. This strategy provides an additional means to fight against respiratory infection in non-vaccinated people, that can be readily translated to human trials. It presents a proof-of-concept for the aerosol delivery of fusion inhibitory peptides to protect against measles and other airborne viruses, including SARS-CoV-2, in case of high-risk exposure.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
MEDLINE
Assunto principal:
COVID-19
/
Sarampo
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
Tópicos:
Vacinas
Limite:
Animais
/
Humanos
Idioma:
Inglês
Revista:
Nat Commun
Assunto da revista:
Biologia
/
Ciência
Ano de publicação:
2022
Tipo de documento:
Artigo
País de afiliação:
S41467-022-33832-6
Similares
MEDLINE
...
LILACS
LIS